tilrekimig (PF-07275315) / Pfizer - LARVOL DELTA

A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20 (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema (clinicaltrials.gov) - P3 | N=375 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Tilrekimig, a trispecific IL-4/IL-13/TSLP antibody, reduces type 2 inflammatory biomarkers in moderate-to-severe atopic dermatitis: Interim biomarker analyses from a randomised, double-blind, placebo-controlled phase 2 trial (EADV 2026) - No abstract available

Biomarker • Clinical • P2 data • Trispecific • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13 • IL4 • TSLP

Phase 2 study of novel trispecific tilrekimig (PF-07275315) in patients with moderate-severe atopic dermititis: Interim efficacy and safety results at 16 weeks (EADV 2026) - No abstract available

Clinical • P2 data • Trispecific • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology

A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20 (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Pfizer

New P1 trial

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema (clinicaltrials.gov) - P3 | N=1375 | Not yet recruiting | Sponsor: Pfizer

Monotherapy • New P3 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Tilrekimig: Initiation of trial for atopic dermatitis (vs dupilimumab) in H2 2026 (Pfizer) - Q2 2026 Results: Initiation of trial for atopic dermatitis (vs placebo) in H2 2026/H1 2027

New trial • Atopic Dermatitis

A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma (clinicaltrials.gov) - P3 | N=1100 | Not yet recruiting | Sponsor: Pfizer

New P3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema (clinicaltrials.gov) - P3 | N=375 | Not yet recruiting | Sponsor: Pfizer

New P3 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

C4531031: A Study to Learn About the Study Medicine Called PF-07275315 in Adults with Moderate-To-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrialsregister.eu) - P1/2 | N=90 | Not yet recruiting | Sponsor: Pfizer Inc.

New P1/2 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

COPD: A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P2/3 | N=1156 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting | Phase classification: P3 ➔ P2/3

Enrollment open • Phase classification • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Pfizer Inc…announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis (Pfizer Press Release) - "The study met its primary efficacy endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75* (≥ 75% reduction in the Eczema Area and Severity Index) at Week 16, compared to placebo. In Stage 2 of the study, which evaluated monthly dosing regimens, tilrekimig showed competitive efficacy....Detailed results from the Phase 2 study of tilrekimig will be submitted to a future medical meeting and a peer-reviewed journal. Pfizer plans to share results from the ongoing portions of the study in the future, pending completion."

P2 data • Atopic Dermatitis

C4531029: A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-to-Severe Asthma (clinicaltrialsregister.eu) - P1/2 | N=90 | Recruiting | Sponsor: Pfizer Inc.

New P1/2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Pfizer Advances New COPD Candidate Into Phase 2/3, Adding Depth to Its Post-COVID Pipeline (The Globe and Mail) - "Pfizer has launched a phase 2/3 trial (NCT07363694) to test its drug PF-07275315 in adults with moderate to severe chronic obstructive pulmonary disease (COPD)...The phase 2 portion is expected to follow patients for about 40 weeks, while the phase 3 portion will extend follow-up to about 68 weeks."

Trial status • Chronic Obstructive Pulmonary Disease • Immunology

COPD: A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P3 | N=1156 | Not yet recruiting | Sponsor: Pfizer

New P3 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Learn More About the Study Medicine PF-07275315 in Healthy Chinese Adult Participants (clinicaltrials.gov) - P1 | N=13 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed

Trial completion

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=340 | Recruiting | Sponsor: Pfizer | Trial primary completion date: Mar 2026 ➔ Jun 2026

Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma (clinicaltrials.gov) - P2 | N=252 | Recruiting | Sponsor: Pfizer

New P2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Learn More About the Study Medicine PF-07275315 in Healthy Chinese Adult Participants (clinicaltrials.gov) - P1 | N=13 | Active, not recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Learn More About the Study Medicine PF-07275315 in Healthy Chinese Adult Participants (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Pfizer

New P1 trial

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=340 | Recruiting | Sponsor: Pfizer | Trial completion date: Feb 2026 ➔ Sep 2026 | Trial primary completion date: Sep 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=340 | Recruiting | Sponsor: Pfizer | Trial primary completion date: Feb 2026 ➔ Sep 2025

Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People (clinicaltrials.gov) - P1 | N=65 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed

Trial completion

A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People (clinicaltrials.gov) - P1 | N=65 | Active, not recruiting | Sponsor: Pfizer | N=36 ➔ 65 | Trial completion date: Dec 2024 ➔ Jun 2024 | Trial primary completion date: Dec 2024 ➔ Jun 2024

Enrollment change • Trial completion date • Trial primary completion date

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=340 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology